Update on the therapy of Behcet disease

被引:89
作者
Saleh, Zeinab [1 ]
Arayssi, Thurayya [2 ]
机构
[1] Tufts Med Ctr, Boston, MA USA
[2] Weill Cornell Med Coll Qatar, Educ City,POB 24144, Doha, Qatar
关键词
Behcet disease; Behcet syndrome; biologic therapy; therapy; treatment; tumor necrosis factor alpha;
D O I
10.1177/2040622314523062
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Behcet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behcet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behcet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.
引用
收藏
页码:112 / 134
页数:23
相关论文
共 197 条
[61]   CLINICAL-EXPERIENCE WITH THALIDOMIDE IN THE MANAGEMENT OF SEVERE ORAL AND GENITAL ULCERATION IN CONDITIONS SUCH AS BEHCETS-DISEASE - USE OF NEUROPHYSIOLOGICAL STUDIES TO DETECT THALIDOMIDE NEUROPATHY [J].
GARDNERMEDWIN, JMM ;
SMITH, NJ ;
POWELL, RJ .
ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (12) :828-832
[62]  
Georgiou S, 1998, J INTERN MED, V243, P367
[63]   Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease [J].
Giansanti, F ;
Barbera, ML ;
Virgili, G ;
Pieri, B ;
Emmi, L ;
Menchini, U .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2004, 14 (05) :445-448
[64]   One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs [J].
Giardina, AnnaRita ;
Ferrante, Angelo ;
Ciccia, Francesco ;
Vadala, Maria ;
Giardina, Ennio ;
Triolo, Giovanni .
RHEUMATOLOGY INTERNATIONAL, 2011, 31 (01) :33-37
[65]   Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study [J].
Gul, Ahmet ;
Tugal-Tutkun, Ilknur ;
Dinarello, Charles A. ;
Reznikov, Leonid ;
Esen, Bahar Artim ;
Mirza, Amer ;
Scannon, Patrick ;
Solinger, Alan .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (04) :563-566
[66]   Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report [J].
Gulli, S ;
Arrigo, C ;
Bocchino, L ;
Morgante, L ;
Sangari, D ;
Castagna, I ;
Bagnato, GF .
BMC MUSCULOSKELETAL DISORDERS, 2003, 4 (1) :1-4
[67]   Behcet's disease in Lebanon: clinical profile, severity and two-decade comparison [J].
Hamdan, A ;
Mansour, W ;
Uthman, I ;
Masri, AF ;
Nasr, F ;
Arayssi, T .
CLINICAL RHEUMATOLOGY, 2006, 25 (03) :364-367
[68]   Pulmonary artery aneurysms in Behcet syndrome [J].
Hamuryudan, V ;
Er, T ;
Seyahi, E ;
Akman, C ;
Tüzün, H ;
Fresko, I ;
Yurdakul, S ;
Numan, R ;
Yazici, H .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 (11) :867-870
[69]   Azathioprine in Behcet's syndrome - Effects on long-term prognosis [J].
Hamuryudan, V ;
Ozyazgan, Y ;
Hizli, N ;
Mat, C ;
Yurdakul, S ;
Tuzun, Y ;
Senocak, M ;
Yazici, H .
ARTHRITIS AND RHEUMATISM, 1997, 40 (04) :769-774
[70]   Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial [J].
Hamuryudan, V ;
Mat, C ;
Saip, S ;
Ozyazgan, Y ;
Siva, A ;
Yurdakul, S ;
Zwingenberger, K ;
Yazici, H .
ANNALS OF INTERNAL MEDICINE, 1998, 128 (06) :443-+